To Study the Absorption, Distribution, Metabolism and Excretion of AZD1305

AstraZeneca

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: AZD1305

Study type: Interventional

Funder types: Industry

Identifiers

NCT00689247

2007-007784-25 (EudraCT No)

D3190C00008

Details and patient eligibility

About

The purpose of this study is to learn more about how AZD1305 is handled by the body, i.e the absorption, distribution, metabolism and excretion of AZD1305.

Enrollment: 10 patients

Sex: Male

Ages: 35 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy volunteers
• A body mass index (BMI=weight/height2) of 19 to 30 kg/m2

Exclusion criteria

• Potassium outside normal reference values
• ECG findings outside normal range

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

10 participants in 2 patient groups

A

Experimental group

Description:

AZD1305 given as oral solution

Treatment:

Drug: AZD1305

Drug: AZD1305

B

Experimental group

Description:

AZD1305 given as iv infusion

Treatment:

Drug: AZD1305

Drug: AZD1305